Trial intelligence / Profile preview

Temozolomide plus short-course radiotherapy versus short-course radiotherapy alone in elderly patients with newly diagnosed glioblastoma

2008-001949-26Phase 3Completed

Sponsor: European Organisation for Research and Treatment of Cancer
Start: Jan 2009
Modality: Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
Countries: 1

Overview

Phase 3, randomised, open-label trial of temozolomide in glioblastoma (GBM) (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Overall survival. Started Jan 2009; status: completed.

Drugs

temozolomide

Conditions

glioblastoma (GBM)

Beyond the preview

Go deeper on 2008-001949-26.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2008-001949-26.